In 2002, Jo Milner, a prominent molecular biologist, introduced a groundbreaking gene-editing technology, which promised significant advancements in medical therapies. However, the innovation was met with substantial backlash, as it sparked profound ethical debates. Critics expressed concerns about the moral implications of genetically altering organisms and the potential ecological risks. The controversy underscored the necessity for regulatory oversight in biotechnology and helped shape ongoing dialogues about the ethical limits of genetic manipulation.